CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC Pharmaceutical Group Limited

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

"DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that "Docetaxel for Injection (albumin-bound)" (the "Product"), a new drug developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.*（石藥集團中奇製藥技術（石家莊）有限公司）, a subsidiary of the Company, has obtained approval granted by U.S. FDA to conduct clinical trials in the U.S..

The Product employs innovative human serum albumin encapsulation technology to deliver docetaxel in nanoparticles into patients. With this technology, the Product will eliminate the need for premedication that is required for all currently marketed docetaxel products, reduce the chance of infusion related hypersensitivity and improve patient compliance. In pre-clinical studies, the Product has demonstrated safety in several animal species and enhanced anti-tumor efficacy in several types of solid tumors. Similar albumin encapsulation technology has been successfully applied in paclitaxel product currently being marketed by the Group.

The Group will conduct clinical development of the Product concurrently in China and the U.S. with the initial solid tumor indications of gastric and prostate cancers.

By Order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 17 September 2020

• For identification purpose only

- 1 -

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Professor LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

- 2 -